Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06433128
Status:
AVAILABLE
Last Update Posted:
2024-05-29
First Post:
2024-05-22
Brief Title:
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Sponsor:
Basilea Pharmaceutica
Organization:
Basilea Pharmaceutica
Study Overview
Official Title:
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options
Status:
AVAILABLE
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection in accordance with the EORTC-MSGERC criteria who have exhausted their treatment options primarily due to an infection with a resistant fungal pathogen and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None